|Papillomas on the right vocal cord|
In this study, the HPV vaccine decreased the incidence of surgeries for recurrent respiratory papillomas in 6 patients.
In another case study, a child who required repeated surgeries to remove recurrent laryngeal papillomas was "cured" after HPV vaccination. In two other studies, this vaccine minimized papilloma formation in the airway of a child (see references below).
Such improvement can also occur with oral papillomas. Specifically, a man in his 60s who suffered from recurrent oral papillomas in spite of multiple excisions was clear of all lesions within 3 months after receiving the quadrivalent HPV vaccine. Interestingly, this patient had HPV-32 which is not part of the HPV vaccine (HPV-16, 18, 6, 11). [Link]
Apparently, these are not isolated cases. In the reported literature, 8 others have noted the same improvement with oral papillomas. Time to improvement was seen within 4 weeks of vaccination and resolution after 3 to 8 months.
Given these promising findings, quadrivalent HPV vaccination may certainly be worth pursuing in any patients of any gender at any age suffering from oral/airway papillomas.
Currently, there are three FDA approved HPV vaccines:
• The bivalent HPV vaccine (Cervarix) which addresses HPV 16 and 18;
• The quadrivalent HPV vaccine (Gardasil) which prevents four HPV types: HPV 16 and 18, as well as HPV 6 and 11;
• And finally Gardasil 9 which prevents 9 HPV types: 6, 11, 16, 18, 31, 33, 45, 52, and 58.
All vaccines are administered through a series of 3 intra-muscular injections over a 6-month period. The second and third doses should be given 2 and 6 months after the first dose.
Of note, our office does offer the HPV spit test to see if HPV is present in the mouth/throat.
Recurrent laryngeal papillomatosis: successful treatment with human papillomavirus vaccination. Arch Dis Child. 2011 May;96(5):476-7. doi: 10.1136/adc.2010.198184. Epub 2011 Jan 10.
Immunological response to quadrivalent HPV vaccine in treatment of recurrent respiratory papillomatosis. Eur Arch Otorhinolaryngol. 2016 Oct;273(10):3231-6. doi: 10.1007/s00405-016-4085-3. Epub 2016 May 17.
Gardasil Vaccination for Recurrent Laryngeal Papillomatosis in Adult Men: First Report: Changes in HPV Antibody Titer. J Voice. 2017 Jan;31(1):104-106. doi: 10.1016/j.jvoice.2016.01.008. Epub 2016 Apr 8.
Effect of Quadrivalent Human Papillomavirus Vaccination on Oral Squamous Cell Papillomas. JAMA Dermatol. Published online September 02, 2015. doi:10.1001/jamadermatol.2015.2805
Intersurgical interval increased with use of quadrivalent human papillomavirus vaccine (Gardasil) in a pediatric patient with recurrent respiratory papillomatosis: A case report. Int J Pediatr Otorhinolaryngol. 2016 Dec;91:166-169. doi: 10.1016/j.ijporl.2016.10.032. Epub 2016 Oct 28.
Therapeutic use of the HPV vaccine in Recurrent Respiratory Papillomatosis: A case report. Int J Pediatr Otorhinolaryngol. 2017 Feb;93:103-106. doi: 10.1016/j.ijporl.2016.12.035. Epub 2016 Dec 27.
Adjuvant Human Papillomavirus Vaccination for Secondary Prevention. JAMA Otolaryngol Head Neck Surg. Published online March 23, 2017. doi:10.1001/jamaoto.2016.4736
Effect of Prophylactic Human Papillomavirus (HPV) Vaccination on Oral HPV Infections Among Young Adults in the United States. J Clin Oncol. 2017 Nov 28:JCO2017750141. doi: 10.1200/JCO.2017.75.0141. [Epub ahead of print]